# Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

> **NCT02024477** · PHASE4 · COMPLETED · sponsor: **George Washington University** · enrollment: 42 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Saxagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02024477
- **Lead sponsor:** George Washington University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2017-09
- **Final completion:** 2017-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02024477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02024477, "Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02024477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*